ASX:ENPPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals
Entropy Neurodynamics Ltd
$0.037
+$0.001 (+1.37%)
Day Range
$0.036 – $0.037
52 Week Range
$0.025 – $0.046
Volume
575.16K
Avg Volume (10D)
1.86M
Market Cap
$60.41M
Price Chart
Market Statistics
Open$0.037
Previous Close$0.037
Day High$0.037
Day Low$0.036
52 Week High$0.046
52 Week Low$0.025
Valuation
Market Cap60.41M
Shares Outstanding1.63B
Price to Book7.39
Trading Activity
Volume575.16K
Value Traded20.95K
Bid$0.036 × 231,090
Ask$0.037 × 121,870
Performance
1 Day-1.35%
5 Day4.29%
13 Week1.39%
52 Week14.06%
YTD10.61%
Technical Indicators
RSI (14)59.07
50-Day SMA$0.034
200-Day SMA$0.034
Latest News
Biotechnology
Entropy Neurodynamics Gains Ethics Approval for Eight-Indication TRP-8803 Trial
Entropy Neurodynamics gains ethics approval for Phase 1b/2a eight-indication TRP-8803 basket trial; first dosing this quarter.
Biotechnology
Entropy Neurodynamics Reports Breakthrough Results from Phase 2a TRP-8802 Study for Treating IBS
Entropy Neurodynamics announces Phase 2a TRP-8802 IBS results: 75% responders, clear gut-brain axis effect; de-risks program ahead of TRP-8803 trials.
Biotechnology
Entropy Neurodynamics' TRP-8803 Trial Shows Repeatable Psychedelic Effects in BED Study
Entropy Neurodynamics reports repeatable psychedelic effects in TRP-8803 BED trial; Cohort 2 enrollment advancing; R&D incentives boost cash runway.
Biotechnology
Entropy Neurodynamics Granted Australian Patent for TRP8803 to Treat Chronic Pain and Psychiatric Conditions
Entropy Neurodynamics (ASX: ENP) granted Australian patent for TRP8803 (IV psilocybin) for chronic pain and neuropsychiatric disorders; protection to 2042.